Jayne Swain
University of Leeds(GB)
Publications by Year
Research Areas
Neuroendocrine Tumor Research Advances, Lung Cancer Research Studies, Neuroblastoma Research and Treatments, Renal cell carcinoma treatment, Thyroid Cancer Diagnosis and Treatment
Most-Cited Works
- → Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial(2023)77 cited
- → Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial(2019)28 cited
- → NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma(2023)20 cited
- → Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial(2024)18 cited
- → NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)(2020)18 cited
- → Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy(2023)16 cited
- → NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).(2022)13 cited
- → Testosterone replacement in young male cancer survivors (TRYMS) - pragmatic adaptation of trial design for a trial struggling with recruitment(2015)4 cited
- → Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer(2021)4 cited
- → Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO.(2024)3 cited